TrialsgrambetaRCTs are beautiful

ANNEXA-I

2024

Andexanet Alfa for Acute Intracerebral Hemorrhage in Patients Receiving a Factor Xa Inhibitor

In 530 patients with factor Xa inhibitor-associated intracerebral haemorrhage, andexanet alfa improved haemostatic efficacy compared with usual care.

Result

Haemostatic efficacy (hematoma expansion ≤35%, NIHSS increase <7, no rescue therapy 3-12 h)
Absolute difference
13.9 points
NNT
8
Effect estimate

adjusted difference13.495% CI 4.6-22.2 · P = 0.003

Absolute difference and NNT are derived from the event rates.

Also reported: Thromboembolic events higher (10.3% vs 5.6%), including ischaemic stroke (6.5% vs 1.5%).

Original publication
Subtopic
factor Xa reversal
Design
Randomised open-label RCT with blinded adjudication, stopped early
Relevance
Important: one of several pillars.
Source
Connolly SJ, et al. N Engl J Med. 2024;390(19):1745-1755.doi 10.1056/NEJMoa2313040

Discussion & critique

Improved haemostasis came with a clear excess of thromboembolic events, and functional outcomes were not improved. Stopped early for efficacy, which tempers precision and enthusiasm for routine use over PCC.

Discussed in podcasts